At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 76 enrolled
Drug / intervention
denosumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
In Brief
A Phase 4 clinical trial evaluating denosumab, teriparatide, and 1 other intervention for Postmenopausal Osteoporosis. Completed, enrolled 76 participants across 1 site.
Detailed Summary
The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide. The study extension will evaluate the effect of one-dose of zoledronic acid after the teriparatide/denosumab combination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartAug 2014
Primary CompletionFeb 2020
TodayJul 2026
First PostedJun 27, 2014
Enrollment StartAug 1, 2014
Primary CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 12.0 years ago
Interventions
denosumabdrug
denosumab subcutaneous injection
teriparatidedrug
teriparatide daily subcutaneous injection
Zoledronic aciddrug
zoledronic acid infusion